Bernd Seizinger

Bernd Robert Seizinger is the founder of CryptoMedix, Inc., founded in 2015, where the title held is Executive Chairman & Chief Executive Officer.
Current jobs include Independent Director at Oncolytics Biotech, Inc. since 2015; Director at Oxford BioTherapeutics Ltd. since 2016; Independent Director at BioInvent International AB since 2018; Director at Karolinska Institutet; Director at Aprea Therapeutics AB since 2015; Director at TriMod Therapeutics Ltd. since 2011; Independent Director at Aprea Therapeutics, Inc. since 2015; Independent Director at Turbine Simulated Cell Technologies Ltd. since 2023.
Former jobs include President & Chief Executive Officer at GPC Biotech AG from 1998 to 2009; Director at Nykode Therapeutics ASA from 2014 to 2024; Independent Director at BioXell SpA from 2010 to 2012; Director-Molecular Neuro-Oncology Laboratory at The General Hospital Corp.
in 1992; Director at Santhera Pharmaceuticals Holding AG from 2004 to 2011; Non-Executive Director at Bionor Pharma ASA; Independent Director at Aptose Biosciences, Inc. from 2022 to 2026; Chief Scientific Officer & Executive VP at Oscient Pharmaceuticals Corp.; Principal at Princeton University; VP-Oncology Drug Discovery & Academic Alliances at Bristol-Myers Squibb Pharmaceutical Research Institute from 1992 to 1996; Associate Professor-Neuroscience at Harvard Medical School in 1992; Member-Supervisory Board at Agennix AG.
Education includes doctorate degrees from Max-Planck-Institute for Molecular Genetics and Ludwig-Maximilians-Universität München.